CV Sciences’ CBD oil will be sold in 945 Kroger-owned stores across 17 states, it was recently announced.
Investors Said Going Public Would Bring Increase in Investments
For biotechs, what’s the path to an initial public offering like? The CEOs of San Diego companies that took the IPO plunge weighed in on this question and others during a recent Biocom panel.
Joan Herman was recently named to the board of Carlsbad’s Ionis Pharmaceuticals.
HEALTH CARE: Reimbursement Codes Open Door for Revenue
The mental health system is often called broken or fragmented. That’s created an opening for San Diego tech companies.
BIOTECH: Pain Relief Device Uses Magnetic Field
NeuraLace Medical, the medical device startup that won last year’s Quick Pitch competition, recently closed on a $3 million seed funding round.
No New Treatments for Targeted Condition in More Than a Decade
La Jolla Pharmaceutical’s stock recently jumped after its drug candidate for regulating iron overload showed promise in preliminary clinical trial results.
Oncternal Retains CEO, Will Remain In San Diego
On the heels of auspicious clinical trial results, San Diego-based Oncternal Therapeutics completed a reverse merger with Tennessee’s GTx, it was announced June 10.
Poway Biz Covers Mind, Body With Its Offerings
For years, when Lillian Markowitz went for her float therapy sessions, she noticed she just couldn’t get out of her own head.
Average Wage Is $115,000; Economic Impact Put at $39B
Employment in San Diego’s life sciences industry increased 12.5% from 2013 to 2018, states a new report.
After securing $30 million in a private stock placement in April, Evofem on June 10 closed a second tranche of $50 million.
UC San Diego Health opened an Encinitas facility as part of a bid to expand beyond hospital walls.
Genomatica acquired Renewable Energy Group's life sciences division on June 6.
Medical Devices: Kaer Biotherapeutics Receives SBIR Grant
Escondido-based Kaer Biotherapeutics received a $300,000 federal grant to help it develop medical technology that could potentially help premature babies and adults with respiratory problems.
The $40M Would Convert Into Shares At 90% of IPO Price
La Jolla-based Inhibrx is prepping for a public debut. Two weeks after raising $40 million, the company in early June filed for an initial public offering to advance three cancer drugs in clinical trials — and other preclinical programs, including an antibiotic.
ER Visits Rose 18% from 2012 to 2017, posing financial and operational difficulties
In 2013, Scripps Mercy Hospital’s emergency department doubled in size after a multiphase revamp. Six years later, Scripps officials said demand caught up.